66346-01-8Relevant articles and documents
Preparation method of 1-(4-chlorphenyl)-4, 4-dimethyl-3-pentanone
-
Paragraph 0020-0046, (2020/12/31)
The invention discloses a preparation method of 1-(4-chlorphenyl)-4, 4-dimethyl-3-pentanone, and relates to the field of organic chemistry, and the preparation method comprises the following specificsteps: in an autoclave, uniformly mixing a raw material shown as a formula (I) with methanol, wherein a mass ratio of the methanol to the raw material shown as a formula (I) is 2-3: 1; adding a catalyst and a cocatalyst into the mixture; replacing gas in a kettle with mixed gas of nitrogen and hydrogen, introducing hydrogen, performing reacting at the temperature of between 40-100 and 0.1-2.0 MPaunder the hydrogenation pressure, and performing pressure relief, filter pressing, water washing and desolvation to obtain the 1-(4-chlorphenyl)-4, 4-dimethyl-3-pentanone after reaction is performed.The method has the beneficial effects that 1) the reaction yield is 98% or above; and the content is more than 98.5%; 2) the catalyst metallic nickel can be used for more than 20 times; and 3) the content of dechlorinated substances is lower than 0.40%.
Design, synthesis and neuraminidase inhibitory activity of N-(5-benzyl-4-(tert-butyl)thiazol-2-yl)benzamides
Wu, Zhilin,Peng, Junmei,Hu, Aixi,Ye, Jiao,Li, Guoxi
, p. 356 - 368 (2016/01/25)
A series of N-(5-benzyl-4-(tert-butyl)thiazol-2-yl)benzamides were synthesized and the structures were characterized by 1H NMR, MS and elemental analyses. The crystal structures of compounds F5 and F16 were determined by single-crystal X-ray diffraction. The neuraminidase inhibitory activities of compounds F1-F32 were evaluated in vitro at the concentration of 40 μg/mL. The results indicated that compounds F8, F26 and F32 exhibited most potent inhibitory activity against NA. Molecular docking was performed by LeDock to further explain the structure-activity relationship of compound F26. The docking modeling showed that compound F26 was in good combination with oseltamivir binding sites of NA and could be a potential NA inhibitor agent.
Process for the hydrogenation of α,β-unsaturated ketones
-
, (2008/06/13)
The catalytic hydrogenation of α,β-unsaturated ketones of the formula in which R1 and R2 independently of one another represent straight-chain or branched alkyl, hydroxy-alkyl, alkenyl, cycloalkyl, cycloalkenyl, aralkyl or aryl, where at least one of the radicals R1 and R2 is monosubstituted to trisubstituted by halogen, can be carried out on a Ni-containing catalyst and in the presence of an organic sulphur compound of the formula in which R3 and R4 independently of one another denote straight-chain or branched alkyl, hydroxy-alkyl, carboxyalkyl or phenyl, and furthermore R3 and R4 may together represent --CH=CH--CH=CH--, --(CH2)4 --, --(CH2)5 --, --(CH2)2 --S--(CH2)2 -- or --(CH2)2 --O--(CH2)2 --, R4 may additionally denote hydrogen or CO--C1 -C12 -alkyl and n assumes the value 0 or 1.